Stefan Chin, MD
Gastroenterology · Daly City, CANPI 1891794152
Payments from drug & device makers
Across 729 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Gilead$2K
- Johnson & Johnson$952
- Takeda Pharmaceuticals U.S.A., Inc.$816
- Ironwood Pharmaceuticals, Inc$662
- plus $4K from 27 others
What the payments were for
- Food & beverage$13,75499%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 193 | $3,354 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 160 | $2,857 |
| Gilead | 86 | $1,693 |
| Johnson & Johnson | 47 | $952 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $816 |
| Ironwood Pharmaceuticals, Inc | 43 | $662 |
| Madrigal Pharmaceuticals | 21 | $582 |
| Nestle Healthcare Nutrition Inc. | 18 | $377 |
| Daiichi Sankyo Inc. | 17 | $340 |
| Aimmune Therapeutics, Inc. | 9 | $251 |
| Ardelyx, Inc. | 12 | $232 |
| Braintree Laboratories, Inc. | 11 | $230 |
| Intercept Pharmaceuticals, Inc. | 10 | $229 |
| Celltrion USA Inc. | 14 | $220 |
| Merck | 10 | $202 |
| Redhill Biopharma Inc. | 7 | $160 |
| Ferring Pharmaceuticals Inc. | 4 | $86 |
| QOL Medical, LLC | 4 | $79 |
| Mauna Kea Technologies, Inc. | 1 | $65 |
| Lilly USA, LLC | 2 | $65 |
| Phathom Pharmaceuticals, Inc. | 2 | $60 |
| Bristol Myers Squibb | 3 | $57 |
| Shionogi Inc | 3 | $51 |
| Pfizer | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $36 |
| Alfasigma USA, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Boston Scientific | 1 | $15 |
| Napo Pharmaceuticals Inc | 1 | $12 |
| Concordia Pharmaceuticals Inc. | 1 | $12 |
| Ambu Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$120
How this compares
$13,846 in reported general payments places this provider in the 80th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 34 | $284,644 |
| ZenpepLipase/Protease/Amylase | 18 | $109,977 |
| VemlidyTenofovir Alafenamide | 36 | $86,870 |
| LinzessLinaclotide | 58 | $65,928 |
| Dexlansoprazole DrDexlansoprazole | 60 | $20,535 |
| Pantoprazole Sodium | 658 | $18,820 |
| Mesalamine | 20 | $18,535 |
| MotegrityPrucalopride Succinate | 24 | $18,105 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 105 | $14,687 |
| Lubiprostone | 62 | $9,006 |
| Famotidine | 136 | $5,197 |
| Ursodiol | 18 | $4,439 |
| Omeprazole | 104 | $2,816 |
| Mercaptopurine | 18 | $1,984 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 23 | $1,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,354 | $350,57292 claims |
| Aimmune Therapeutics, Inc.Zenpep | $251 | $109,97718 claims |
| GileadVemlidy | $1,693 | $86,87036 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $816 | $18,10524 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $2,857 | $14,687105 claims |
| Braintree Laboratories, Inc.Suflave | $230 | $1,46312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Daly City
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
- Brigid BolandSan Diego$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.